Bone scanning in lung cancer: Authors' reply

doi:10.1136/bmj.329.7459.231-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Martin Hetzel (martin.hetzel@medizin.uni-ulm.de), consultant physician,
Coskun Arslandemir, physician,
Holger Schirrmeister, consultant in nuclear medicine

Department of Internal Medicine II, University of Ulm, D-89081 Ulm, Germany
Department of Internal Medicine II, University of Ulm, D-89081 Ulm, Germany
Department of Nuclear Medicine, University of Ulm

EDITOR—Benamore et al assume that our incidence of bone metastases was high because of the unusually high proportion of patients with small cell lung cancer. The incidence of distant metastases is 30-50% at initial presentation of non-small cell lung cancer.1 The incidence of bone metastases was highest in the small cell variety at initial presentation but was identical at necropsy in the four main types.2 Many bone metastases are therefore likely to be missed at initial diagnosis of non-small cell lung cancer. …